Anagenics Limited · ASX:AN1
Anagenics — Cellmid — Investor Presentation (October 2018)
30 slides from Anagenics's investor presentation, Oct 31, 2018
Slide 1: Investor Presentation
Investor Presentation 31st October / 1st November 2018 ASX: CDY
Slide 2: Focus on scaling distribution and extracting midkine value
Focused on rapidly scaling the multi-channel distribution of flagship, clinically proven product ranges in Asia, USA and Australia. “I feel younger, you know, Continue to extract value from midkine drug development and patent portfolio; recent preclinical results add value creation opportunities lik
Slide 3: Company Overview
COMPANY OVERVIEW Cellmid has three wholly owned subsidiaries operating in two distinct business segments. CONSUMER HEALTH PRE-CLINICAL THERAPEUTIC ASSETS ADVANGEN Anti-aging functional cosmetics and consumer health products for hair, face and wellbeing. Product range includes and KINERA LYRAMID Midk
Slide 4: Investment Highlights
INVESTMENT HIGHLIGHTS Proprietary, Exposure to the fast Existing distribution Highly experienced High growth phase Midkine drug clinically validated growth anti-aging networks in board and with new product portfolio products that segment of the Australia, Japan, management team rollout & distributio
Slide 5: A Strong Board
A STRONG BOARD A vibrant mix of global retail, life sciences and finance experience Dr David King | Chairman Maria Halasz | CEO and Managing Director GOVERNANCE ENTREPRENEURSHIP LIFE SCIENCES RETAIL FINANCE ENTREPRENEURSHIP An experienced independent chairman with expertise in high With 24+ years in
Slide 6: Recent Achievements
RECENT ACHIEVEMENTS Continue momentum in Q1 • Customer receipts up 100% in Q1 from same period in FY18 to $2.01M • Consumer health sales at $1.55M for the quarter, up 50% • US retail expansion with 16 stores launched including Bloomingdales and Neiman Marcus New product launches • Fillerina – non-in
Slide 7: Advangen
CELLMID © ADVANGEN Positive Aging
Slide 8: What is évolis?
WHAT IS ? is a clinically validated, TGA listed portfolio of haircare treatment products specifically formulated as an anti-aging hair solution, combining science and nature to bring back your best hair. is the culmination of over 10 years of dedicated research into hair growth and hair biology. The
Slide 9: How does évolis work?
HOW DOES WORK ? • FGF5 is a naturally occurring protein and critical in the hair cycle • Its role is to signal hair to stop growing • Blocking FGF5 can extend the growth phase of hair resulting in increased hair growth, reduced hair loss and longer, stronger and thicker hair • évolis is based on nat
Slide 10: Addressing a Global Hair Growth Problem
ADDRESSING A GLOBAL HAIR GROWTH PROBLEM USA 18 million men and women suffer from hair loss in the US PRODUCT RANGE • 13% of women experience hair loss by 40 increasing up to 50% by age 70 and • 50% of men experience significant hair loss by age 50 PROFESSIONAL Reverse, Prevent, Promote CHINA 185 mil
Slide 11: Market Opportunity
MARKET OPPORTUNITY ANTI-AGING GLOBAL HAIRCARE HAIRLOSS forecast to grow MARKET 24% Forecasted to reach 2018-2022 with emerging US$11.8B markets expected to generate double digit growth3 by 2024 1 GLOBAL HAIRCARE MARKET outperformed fast is estimated to be growing anti-aging haircare market generatin
Slide 12: Competitive Landscape
COMPETITIVE LANDSCAPE évolis® is the only anti-aging haircare product that is based on natural ingredients, clinically and scientifically validated évolis ticks all the boxes ® and effective in reducing hair loss and increasing hair growth évolis vs. other anti-aging brands2. ® évolis® has significa
Slide 13: What is Fillerina?
WHAT IS FILLERINA® ? Fillerina® is the first non-injectable transdermal filler that has been clinically validated to reduce wrinkles and increase facial volume. The Fillerina® treatment combines six hyaluronic acids to facilitate the filling in and plumping up of tissues. In December 2014, Wiley pub
Slide 14: The Distribution Agreement
THE DISTRIBUTION AGREEMENT • Fillerina® launch in Australia and now available in WHY FILLERINA® ? pharmacies from October • Advangen has entered into an agreement with Labo International to undertake the exclusive distribution of • First in class, best in class non-injectable Fillerina® in AU & NZ t
Slide 15: Strong Revenue Growth in Advangen; FY2019 Expected Breakout Year
STRONG REVENUE GROWTH IN ADVANGEN; FY2019 EXPECTED TO BE A BREAKOUT YEAR FY2018 revenue up 26% Q1 FY2019 revenue up 50% (compared to PCP) Acquired in 2013 from Japanese owners with revenues increasing 4.7X since acquisition Advangen revenue A$ million Sales in three markets to date: Japan, Australia
Slide 16: Growth Drivers
GROWTH DRIVERS Growth is expected to come from four broad categories: New products • Extension of the product range (new products, refer to right) Revive & Lift Spray • Distribution channel expansion in existing markets Non-comedogenic dry • Geographical expansion within USA, China and entry into ot
Slide 17: Australia
AUSTRALIA Existing Channels • E-commerce: Dedicated global website launched in April 2018, including the AU portal • Pharmacy: évolis® products are stocked in over 1,800 pharmacies (up from 1,000 in FY2017) accounting for around 35% of the market • Servicing selected premium salons to be featured re
Slide 18: Japan Highlights
JAPAN Existing Channels HIGHLIGHTS • QVC TV shopping: Continue to market through television shopping channel QVC Japan, providing exposure to 26 million households. QVC Japan accounts for 65% of Japanese revenue. • Barbershops: Service barbershop network via Japan’s largest wholesaler, Nichiri • Con
Slide 19: USA Highlights
USA Existing Channels HIGHLIGHTS • E-commerce: Currently limited activity (to increase after the launch of fully operational website) • Premium retail: Partnerships entered into with Neiman Marcus, Soft Surroundings and Bloomingdales • Thirteen store launches completed in Q1 FY2019 • Comprehensive P
Slide 20: China
CHINA Existing and near term channels • Distribution agreement: Exclusive five-year agreement signed in May 2018 with Fukangren Bio- Pharm Tech. Co. Ltd for the distribution of évolis® lotions and shampoos to over 500 pharmacies, associated hospitals and clinics in China. The agreement is spilt into
Slide 21: Business Performance & Outlook
BUSINESS PERFORMANCE & OUTLOOK 21
Slide 22: Financial Performance – Q1 FY2019
FINANCIAL PERFORMANCE – Q1 FY2019 Q1 FY2019 Q1 FY2018 % chg Key Q1 FY2019 developments: • Successful placement & SPP raising Consumer health sales 1.55 1.03 Up 50% $10.03m (ex costs) Key cash flow items • Repaid $1.0M of $2.0M R&D loan facility Cash receipts (inflow) 2.01 1.01 Up 100% • Ramp-up in p
Slide 23: Financial Performance – FY2018
FINANCIAL PERFORMANCE – FY2018 Year FY2018 FY2017 (A$’Ms) (A$’Ms) % chg FY2018 commentary: Consumer health revenue 5.64 4.49 Up 26% • Revenue and other income growth of 23% driven by strong performance of consumer R&D tax and grants 1.06 0.83 Up 27% sales division Total revenue & other income 6.83 5
Slide 24: Lyramid & Kinera: Midkine in therapy
Lyramid & Kinera Midkine in therapy 24
Slide 25: Midkine – A Novel and Compelling Target
MIDKINE – A NOVEL AND COMPELLING TARET Discovered in 1988, midkine is the subject of over 815 publications (300+ in oncology) • CDY has the largest portfolio of midkine IP assets globally with several Midkine Overexpression relative to healthy tissue Tissue Blood Urine potential clinical development
Slide 26: Lyramid and Kinera
LYRAMID KINERA • Stage: pre-clinical • Stage: pre-clinical • Drug class: Antibodies CAB101 and CAB102 (cancer, • Drug class: Protein, MK fibrosis, chronic kidney disease, myocarditis) and companion diagnostic marker • Applications: heart failure, chronic heart conditions and ischemia related complic
Slide 27: Objectives for Lyramid & Kinera
OBJECTIVES FOR LYRAMID & KINERA Complete pre-clinical studies • Clinical indications will be assessed on the strength of pre-clinical evidence during FY2019 • Focused on capital preservation - partnerships are the preferred strategic approach to pursue clinical development phase Complete pre-clinica
Slide 28: Appendices
9 = = a _ LL O APPENDICES 28
Slide 29: Who are QVC?
WHO ARE QVC? QVC is a multiplatform shopping experience engaging millions QVC Global Scale of shoppers with hundreds of brands globally through online, Country TV Homes Channels broadcasting, mobile and social channels. (Millions) United States 104 3 The QVC business model allocates sales event time
Slide 30: Disclaimer
DISCLAIMER Forward looking statements This presentation contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the state